Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ...

In this analysis, we explore the potential upside for Merck despite its short-term hurdles.

Injectable antibodies targeting PCSK9 have failed to take off as expected in the cholesterol-lowering market, but Merck & Co hopes to do much better with an oral alternative. MK-0616 has been ...

Merck’s potential for upside hinges on its ability to execute on several key fronts: successfully advancing its pipeline, expanding geographically, and making strategic acquisitions.

Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

Besides working on various strategies to drive Keytruda's long-term growth, Merck is also pinning hopes on its new 21-valent pneumococcal conjugate vaccine, Capvaxive, and pulmonary arterial ...

AstraZeneca has reported the first clinical data with its oral PCSK9 inhibitor AZD0780, playing catch-up with rival MSD.

Leading companies, such as Incyte Corporation, TWi Biotechnology, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, and others, are actively advancing promising drug candidates aimed at improving ...

A new study projects that aligning U.S. cholesterol treatment with clinical guidelines could significantly reduce cardiovascular events nationwide. The study, led by researchers at Baltimore-based ...

Merck faces a looming challenge with the 2028 patent expiration of Keytruda, but it’s not sitting around twiddling test tubes. The company has 20 potential blockbuster drugs in its pipeline worth a ...

Merck MRK has reached a significant support level, making it an attractive option for investors from a technical standpoint. Since early June, the stock has broken through its 50-day simple moving ...